When Roche first began maneuvering to take complete control of Genentech, the air was thick with speculation that the Swiss drug giant’s plans would force out some of the South San Francisco company’s top talent.
Sure enough, upon completing the deal last month, Roche announced that Susan Desmond-Hellmann, Genentech’s president of product development, would give up that job midyear and thereafter be an adviser.
But Desmond-Hellmann has landed on her feet, though at somewhat of a pay cut. On Thursday was named chancellor of the University of California at San Francisco, effective Aug. 3.
A former medical intern and assistant professor at the university, she will earn $450,000 a year as chancellor. Her compensation at Genentech included $725,666 in base pay and $1.3 million in incentives other than stock-based compensation, according to UCSF.